Cutaneous adverse events caused by aromatase inhibitors have been reported to be rare. We describe a rare case of a cutaneous adverse event that developed in a cancer-affected breast after aromatase inhibitor treatment. A 72-year-old postmenopausal female patient who was diagnosed with stage IA breast cancer received anastrozole as adjuvant treatment. Six months after the initiation of anastrozole, she developed an irregularly shaped purpuric plaque with several purpuric papules surrounding the postoperative scar on her left breast. Histological findings revealed capillary vessel proliferation and expansion, with hemorrhage in the superficial dermis. Immunohistochemistry of the skin biopsy specimen revealed hormone receptor expression limited to the vascular endothelial cells of the proliferating and expanding vessels. We believe that anastrozole induced a change in the local estrogen level, which affected the hormone receptor-positive endothelial cells in the dermis near the primary lesion of the breast cancer and caused a cutaneous adverse event only in the aforementioned area.
Introduction
Aromatase inhibitors (AIs) are commonly used for hormone receptor-positive breast cancer both in the early stage, as adjuvant treatment, and in the advanced stage. Three AIs (anastrozole, letrozole, and exemestane) suppress the plasma estrogen level by inhibiting or inactivating aromatase. Although cutaneous adverse events caused by these AIs have been reported to be rare [1] , we experienced a very rare case of a cutaneous adverse event due to anastrozole that was localized to the area around the postoperative scar from mastectomy.
Case Report
A 72-year-old, postmenopausal female patient who was diagnosed with breast cancer underwent left breast mastectomy and sentinel lymph node biopsy. The postoperative diagnosis was invasive ductal carcinoma, and no metastases were found in the sentinel lymph nodes (T1N0M0, stage IA). The tumor cells were positive for the estrogen receptor (ER) and progesterone receptor (PR), but negative for the human epidermal growth factor receptor 2 (HER2). She was started on 1 mg of anastrozole daily as adjuvant treatment and did not receive radiotherapy.
Six months after the initiation of anastrozole, she developed a hard, irregularly shaped erythema surrounding the postoperative scar on the left breast. Results of the skin biopsy revealed no evidence of skin metastasis of the breast cancer. She was referred to us because the erythema gradually expanded and changed to an indurated purpuric plaque. Fixed drug eruption was considered as the differential diagnosis; however, topical steroid and anti-allergy medicine did not improve the symptom. Additionally, several purpuric papules developed in the purpura (Fig. 1a) ; thus, another skin biopsy that included the new papule was performed.
Histological findings of the second biopsy specimens showed the proliferation and expansion of capillary vessels with hemorrhage in the superficial dermis ( Fig. 2a-c ). There was no obvious change to suggest drug eruption, vasculitis, or evidence of skin metastasis of the breast cancer. A few days after the cessation of anastrozole, the purpura rapidly disappeared (Fig. 1b) . As the grade of the cutaneous change was not severe, anastrozole was readministered to the patient after a month of interruption. Eighteen months after readministration, there was no evidence of another cutaneous adverse event related to anastrozole treatment or the recurrence or metastasis of breast cancer.
Discussion/Conclusion
The molecular subtypes of breast cancer are determined using the hormone receptor status and HER2 status of the tumor cells. Treatment decisions are made with consideration of the tumor stage, tumor grade, and molecular subtype. Our patient was postmenopausal, had hormone receptor-positive breast cancer, and received anastrozole as adjuvant treatment.
The growth and metastasis of hormone receptor-positive breast cancer is stimulated by estrogen. The aromatase enzyme is responsible for estrogen biosynthesis from androgen in postmenopausal women. AIs suppress the plasma and intratumoral estrogen level by blocking the aromatase enzyme and exhibit an antitumor effect in the treatment of postmenopausal, hormone receptor-positive breast cancer.
Common adverse events associated with AIs are an increased risk of bone fracture, arthralgia, myalgia, and other musculoskeletal disorders. Complaints related to the skin such as rash, pruritus, dry skin, and acne appear less frequently [2] . However, rare cutaneous adverse events such as cutaneous vasculitis [1, [3] [4] [5] , erythema nodosum [6] , subacute cutaneous lupus erythematosus [7] , lichen sclerosus vulvae [8] , erythema multiforme [9] , and erythema multiforme-like eruption [10] have been reported. A previous report suggested that inhibition of the estrogen effect, which prevents the pathogenesis of vasculitis, may paradoxically induce vasculitis [4] . The mechanism leading to other cutaneous adverse events has not been clearly explained. In our case, the cutaneous lesion was localized to the area around the mastectomy scar. There have only been two reports of a cutaneous adverse event limited to the canceraffected breast [5, 10] .
The local onset of a cutaneous disorder was supposedly explained by the concept of the immunocompromised district of skin [11] . The immunocompromised district is a skin area more vulnerable than the rest of the body due to the local dysregulation of immune control and is thought to be caused by several factors such as chronic lymphatic stasis, herpetic infection, ionizing or ultraviolet radiations, and various types of trauma. In two previously reported cases of a limited cutaneous adverse event related to anastrozole treatment, both patients had undergone radiation therapy and one experienced lymphedema [11] . Our patient did not undergo radiation therapy or lymph node dissection; therefore, the local condition of her left breast that caused the limited cutaneous lesion was not likely explained by the concept of the immunocompromised district of skin.
In postmenopausal women, extragonadal sites such as mesenchymal cells of the adipose tissue and skin, bone, and brain express aromatase and become the main source of estrogen. The estrogen produced by breast adipose tissue is strongly implicated in promoting the development and growth of ER-positive breast cancer [12] . Shibahara et al. [13] reported that the aromatase status of a primary tumor generally represents the status of metastatic lymph nodes, and aromatase immunoreactivity was detected in the adipose tissue surrounding the lymph node. The endocrine environment of an ER-positive tumor remains stable during the metastatic process. In our case, we considered the possibility that this endocrine environment, which was related to the development of a cutaneous adverse event, was limited to the canceraffected breast.
Immunohistochemistry of the skin biopsy specimen was performed, and ER/PR expression was observed in the vascular endothelial cells of the proliferating and expanding vessels in the superficial dermis (Fig. 3a-d) . Extravasation of erythrocytes was also observed around the proliferating vessels with hormone receptor-positive endothelial cells, which reflects the clinical manifestation of purpura. There was no ER/PR expression in the other vessels in the dermis without proliferation. In a postmenopausal, non-breast cancer patient, ER/PR expression was not observed in the skin of the breast or adipose tissue (Fig. 3e, f) . We believe that AIs induced a change in the local estrogen level, which affected the proliferating ER/PR-positive endothelial cells in the dermis near the primary lesion of the breast cancer and caused a cutaneous adverse event only in the aforementioned area.
We initially considered whether therapeutic alteration was necessary because the cutaneous change in our patient seemed to be skin metastasis of the breast cancer based on its appearance or drug eruption due to anastrozole. However, if her cutaneous lesion was caused by the change in the local estrogen level induced by anastrozole, like we thought, it might indicate the effect of the treatment against tumor progression. In that case, continuation of the anastrozole treatment will be preferable. Figure 2 . Magnification: ER, ×100 (a); PR, ×100 (b); ER, ×200 (c), PR, ×200 (d). In a postmenopausal, non-breast cancer patient, ER/PR expression is not observed in the skin of the breast or adipose tissue. Magnification: ER, ×40 (e), PR, ×40 (f).
